Tratamiento farmacológico de la obesidad.

More than 70% of the population in Mexico is overweight or obese, affecting mainly people in productive age. Obesity is associated with the development of diseases that increase cardiovascular risk (diabetes mellitus, hypertension or atherogenic dyslipidemia), diseases that limit the quality of life...

Descripción completa

Detalles Bibliográficos
Publicado en:Revista Medica del IMSS Vol. 56; no. 4; pp. 395 - 410
Autores principales: Ferreira-Hermosillo, Aldo, Salame-Khouri, Latife, Cuenca-Abruch, Dalia
Formato: Artículo
Publicado: Direccion de Prestaciones Medicas - IMSS jul/ago2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=133359057&site=ehost-live
header:
  @attributes:
    shortDbName: lth
    uiTerm: 133359057
    longDbName: MedicLatina
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        04435117
        7L1
      jtl: Revista Medica del IMSS
      issn: 04435117
      maglogo: N
    pubinfo:
      dt: jul/ago2018
      vid: 56
      iid: 4
      pid: 20867
      pub: Direccion de Prestaciones Medicas - IMSS
    artinfo:
      ui: 133359057
      ppf: 395
      ppct: 15
      formats:
        fmt:
          @attributes:
            type: P
            size: 3.7MB
      tig:
        atl: Tratamiento farmacológico de la obesidad.
      aug:
        au:
          Ferreira-Hermosillo, Aldo
          Salame-Khouri, Latife
          Cuenca-Abruch, Dalia
        affil:
          Instituto Mexicano del Seguro Social, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad de Investigación Médica en Endocrinología Experimental. Ciudad de México, México
          Centro Médico American British Cowdray, Departamento de Medicina Interna. Ciudad de México, México
      sug:
      keyword:
        Adrenergic Agents
        Anti-Obesity Agents
        Glucagon-Like Peptide 1
        Obesity
        Serotonin Agents
        Adrenérgicos
        Fármacos Antiobesidad
        Obesidad
        Péptido 1 Similar al Glucagón
        Serotoninérgicos
      ab:
        More than 70% of the population in Mexico is overweight or obese, affecting mainly people in productive age. Obesity is associated with the development of diseases that increase cardiovascular risk (diabetes mellitus, hypertension or atherogenic dyslipidemia), diseases that limit the quality of life of the patient (osteoarthrosis or sleep apnea) and even with the increase in the incidence of certain types of cancer (breast or colon). It is evident that the decrease of at least 5% of body weight induces improvement in all these factors; however, in some patients it is difficult to achieve this goal only with lifestyle modifications. In this review we analyze some drugs approved for weight control by national and international agencies that can serve as an auxiliary in conjunction with diet and exercise. Treatment must be individualized according to each patient characteristics, with an adequate evaluation of their risks and benefits.
        Más del 70% de la población en México padece sobrepeso u obesidad, que afectan principalmente a personas en edad productiva. La obesidad se asocia con el desarrollo de enfermedades que incrementan el riesgo cardiovascular (diabetes mellitus, hipertensión arterial o dislipidemia aterogénica), así como a enfermedades que limitan la calidad de vida del paciente (osteoartrosis o apnea del sueño) y al incremento en la incidencia de ciertos tipos de cáncer (mama o colon). Es evidente que la disminución de al menos 5% del peso corporal induce mejoría en todos estos factores; sin embargo, en algunos pacientes es difícil alcanzar esta meta únicamente con modificaciones en el estilo de vida. En esta revisión se analizan algunos medicamentos aprobados para el control de peso por organismos nacionales e internacionales que pueden servir como auxiliares en conjunto con la dieta y el ejercicio. El tratamiento debe ser individualizado y deben evaluarse adecuadamente sus riesgos y beneficios.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: Spanish
    refInfo:
    copyright:
      @attributes:
        flag: Y
      custom: Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use.
      item: Revista Medica del IMSS
      holder: Direccion de Prestaciones Medicas - IMSS
      dt:
        @attributes:
          year: 2018
    holdings:
      @attributes:
        islocal: N